---
figid: PMC4852160__nihms743175f1
figtitle: Adenosine monophosphate-activated protein kinase (AMPK) activators for the
  prevention, treatment and potential reversal of pathological pain
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
pmcid: PMC4852160
filename: nihms743175f1.jpg
figlink: /pmc/articles/PMC4852160/figure/F1/
number: F1
caption: Trk receptors, such as the NGF receptor TrkA, the gp120 protein, which transduces
  IL6 signals and GPCRs responsible for detecting inflammatory mediators are capable
  of signaling via mTORC1 and MAPK pathways in nociceptive DRG and/or TG neurons.
  AMPK activation negatively regulates these signaling events via phosphorylation
  of a number of key signaling molecules. AMPK phosphorylates the Trk receptor signaling
  adaptor protein IRS at Ser789. This results in dampened signaling via Trks and may
  also negatively influence gp120 signaling. A key phosphorylation event for downstream
  regulation of mTORC1 signaling by AMPK is TSC1-2 phosphorylation at Ser 1227 and/or
  Ser 1345. Both of these phosphorylation events reduce signaling via the mTORC1 pathway
  in an AMPK activation-dependent fashion. Finally, B-raf phosphorylation at Ser 729
  by AMPK decreases MAPK signaling since this small GTPase is a key signaling molecule
  linking receptors to MAPK signaling pathways. A potential consequence of AMPK activator-mediated
  decreases in MAPK signaling is a decrease in the phosphorylation of voltage-gated
  sodium channels such as Nav1.7 which can lead to a reduction in excitability of
  DRG or TG neurons.
papertitle: Adenosine monophosphate-activated protein kinase (AMPK) activators for
  the prevention, treatment and potential reversal of pathological pain.
reftext: Theodore J. Price, et al. Curr Drug Targets. ;17(8):908-920.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9339299
figid_alias: PMC4852160__F1
figtype: Figure
redirect_from: /figures/PMC4852160__F1
ndex: 4a60d0f7-df09-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4852160__nihms743175f1.html
  '@type': Dataset
  description: Trk receptors, such as the NGF receptor TrkA, the gp120 protein, which
    transduces IL6 signals and GPCRs responsible for detecting inflammatory mediators
    are capable of signaling via mTORC1 and MAPK pathways in nociceptive DRG and/or
    TG neurons. AMPK activation negatively regulates these signaling events via phosphorylation
    of a number of key signaling molecules. AMPK phosphorylates the Trk receptor signaling
    adaptor protein IRS at Ser789. This results in dampened signaling via Trks and
    may also negatively influence gp120 signaling. A key phosphorylation event for
    downstream regulation of mTORC1 signaling by AMPK is TSC1-2 phosphorylation at
    Ser 1227 and/or Ser 1345. Both of these phosphorylation events reduce signaling
    via the mTORC1 pathway in an AMPK activation-dependent fashion. Finally, B-raf
    phosphorylation at Ser 729 by AMPK decreases MAPK signaling since this small GTPase
    is a key signaling molecule linking receptors to MAPK signaling pathways. A potential
    consequence of AMPK activator-mediated decreases in MAPK signaling is a decrease
    in the phosphorylation of voltage-gated sodium channels such as Nav1.7 which can
    lead to a reduction in excitability of DRG or TG neurons.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Il6
  - Ngf
  - Gpbar1
  - ras
  - Hras
  - Kras
  - Rem1
  - Pik3r1
  - Zhx2
  - Mdk
  - Akt1
  - Ephb2
  - Mapk1
  - Tsc2
  - Tsc1
  - Atp7a
  - Eif4e
  - Ntrk1
  - IL6
  - NGF
  - FZD4
  - NMUR1
  - LPAR3
  - LGR6
  - MRGPRX3
  - MRGPRX4
  - GPR151
  - OXER1
  - GPRC6A
  - MRGPRX1
  - VN1R17P
  - GPR166P
  - GRM1
  - GRM2
  - GRM3
  - GRM4
  - GRM5
  - GRM6
  - GRM7
  - GRM8
  - CASR
  - GABBR1
  - GABBR2
  - GPR156
  - GPR158
  - GPR179
  - GPRC5A
  - GPRC5B
  - GPRC5C
  - GPRC5D
  - KRAS
  - HRAS
  - NRAS
  - IARS1
  - IRS1
  - IRS2
  - IRS4
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - AKT1
  - AKT2
  - AKT3
  - EPHB2
  - MAPK1
  - MAPK3
  - TSC2
  - TSC1
  - CCL26
  - ATP7A
  - EIF4E
  - EIF4E2
  - EIF4E3
  - MTOR
  - RPTOR
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - NTRK1
  - ITIH4
  - Tas2r134
  - Rxfp2
  - Pik3cg
  - Prkaa2
  - Ephb1
  - na
  - Oamb
  - Ras64B
  - Ras85D
  - IRSp53
  - IleRS
  - chico
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Dsor1
  - Mtk
  - SNF4Agamma
  - AMPKalpha
  - Akt
  - Erk7
  - rl
  - gig
  - lok
  - Thor
  - eIF4E1
  - eIF4E7
  - eIF4E4
  - eIF4E5
  - eIF4E3
  - eIF4E6
  - eIF4EHP
  - Crtc
  - MKP-4
  - p38b
  - Glg1
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
